Relating to immunity from liability for public and open-enrollment charter school campuses that maintain a supply of epinephrine auto-injectors for emergency use.
Impact
The bill's passage would amend the Education Code, specifically Section 38.0151, to support policies for the care of students at risk for anaphylaxis. By stipulating that governmental entities are not liable if someone administers an epinephrine auto-injector in good faith, the legislation encourages schools to stock these vital medical supplies without the fear of litigation. This change is significant for schools that often face challenges in catering to the medical needs of students with allergies, thereby promoting a safer environment on school campuses.
Summary
SB28 aims to provide a framework for public and open-enrollment charter school campuses to maintain a supply of epinephrine auto-injectors for emergency use. The bill establishes that schools may administer these auto-injectors to individuals experiencing an anaphylactic reaction and specifies that such administration will not be considered unlawful practice by health care professionals. This provision is crucial for ensuring the safety of students who may suffer from severe allergic reactions, providing necessary medical treatment promptly in the event of an emergency.
Sentiment
The sentiment surrounding SB28 has been predominantly positive among legislators and education advocates who recognize the importance of addressing students' medical needs. Supporters argue that the bill reflects a commitment to student health and safety, particularly for those at risk of life-threatening allergic reactions. Nonetheless, some concerns have been raised regarding the practicalities of implementation in schools, such as ensuring proper training for personnel on how to administer the auto-injectors correctly.
Contention
While there is broad support for the intent of SB28, discussions have pointed out potential issues regarding liability and the responsibilities of school staff. Opponents of aspects of the bill have expressed concern that the legislation could inadvertently lead to situations where untrained personnel may administer epinephrine inappropriately, thereby resulting in harm. However, the bill includes immunity provisions designed to mitigate these risks, indicating a legislative balance between ensuring health safety and protecting school personnel.
Relating to the use of epinephrine auto-injectors and medication designated for treatment of respiratory distress on public and private school campuses.
Relating to the use of opioid antagonists on the campuses of public and private schools and institutions of higher education and at or in transit to or from off-campus school events.
Relating to the maintenance, administration, and disposal of opioid antagonists on public and private school campuses and to the permissible uses of money appropriated to a state agency from the opioid abatement account.
Relating to the maintenance, administration, and disposal of opioid antagonists on public and private school campuses and to the permissible uses of money appropriated to a state agency from the opioid abatement account.
Relating to the operation of open-enrollment charter schools, including enrollment procedures and the applicability of certain laws to open-enrollment charter schools.
Relating to the establishment of a grant program for school districts or open-enrollment charter school campuses that are designated as full-service community schools.
Relating to policies and training regarding the use of epinephrine auto-injectors by school districts and open-enrollment charter schools; providing immunity.